Podcasts about pcsk9

Managing cholesterol is a key part of preventing cardiovascular disease, and nurses are on the front lines of patient care. In this episode, we explore the main cholesterol-lowering medications, including statins, ezetimibe, PCSK9 inhibitors, fibrates, and more. You'll learn how each medication works, important side effects, lab monitoring, and nursing considerations for safe administration. We'll also cover strategies for educating patients and supporting long-term adherence. By the end of this episode, you'll have practical tools to confidently recognize, monitor, and teach about cholesterol medications in everyday nursing practice. Your support helps me provide more free resources like this! Consider supporting and getting more amazing pharmacology content! Head on over to meded101.com/nurse

A phase 3 trial in The New England Journal of Medicine found that the oral PCSK9 inhibitor enlicitide reduced LDL by 57% at 24 weeks in high-risk patients, with similar adverse events to placebo. An oral option may improve uptake and help more patients reach lipid targets. In The Lancet, SMART-CHOICE 3 showed clopidogrel monotherapy after DAPT post-PCI reduced death, MI, or stroke versus aspirin, without more bleeding. Finally, a large meta-analysis confirmed most reported statin side effects are not causally linked, reinforcing their strong benefit–risk profile.

Program notes:0:38 Removal of fallopian tubes to prevent ovarian ca1:43 129 studies included2:43 Women who no longer desire pregnancy3:40 Technically feasible4:30 New oral PCSK9 inhibitor5:35 Think it's a slam dunk6:08 EHR helping deprescribing in older adults7:08 Two sequential EHR interventions8:08 40% more likely in one group9:08 Something in email less effective9:50 Benefits of knee braces for OA10:50 Brace specific to area of OA12:00 If it results in a placebo effect13:00 End

In this pharmacology podcast episode, we focus on two key non-statin cholesterol-lowering therapies: ezetimibe and PCSK9 inhibitors (Click here to listen to the statin podcast episode). These agents play a role in lipid management, particularly for patients who are unable to reach LDL cholesterol goals with statins alone or who have statin intolerance. Ezetimibe works by inhibiting the absorption of dietary and biliary cholesterol at the brush border of the small intestine. By reducing the amount of cholesterol delivered to the liver, ezetimibe lowers circulating LDL cholesterol by approximately 15 to 25 percent. It is taken orally once daily and is commonly used as add-on therapy to statins in patients with established atherosclerotic cardiovascular disease or high baseline LDL levels. Ezetimibe is generally well tolerated, with a favorable safety profile and minimal systemic exposure, making it an attractive option in older adults and patients with multiple comorbidities. PCSK9 inhibitors, including alirocumab and evolocumab, offer a much more potent LDL-lowering effect. These monoclonal antibodies work by blocking PCSK9, a protein that promotes degradation of LDL receptors in the liver. By preserving LDL receptors, PCSK9 inhibitors enhance clearance of LDL cholesterol from the bloodstream, often reducing LDL levels by 50 to 60 percent. They are administered via subcutaneous injection every two to four weeks and are most commonly used in patients with familial hypercholesterolemia, established cardiovascular disease, or persistently elevated LDL despite maximally tolerated statin and ezetimibe therapy. Be sure to check out our free Top 200 study guide – a 31 page PDF that is yours for FREE! Support The Podcast and Check Out These Amazing Resources! NAPLEX Study Materials BCPS Study Materials BCACP Study Materials BCGP Study Materials BCMTMS Study Materials Meded101 Guide to Nursing Pharmacology (Amazon Highly Rated) Guide to Drug Food Interactions (Amazon Best Seller) Pharmacy Technician Study Guide by Meded101

This week, Dr. Kahn breaks down a new paper examining the risks and reported side effects of statins—including the surprising finding that placebo alone is linked to many of the same symptoms. He also covers an oral PCSK9 inhibitor currently under study and what it could mean for cholesterol management. The episode then dives into the latest research on emerging therapies designed to lower lipoprotein(a), including a real-world case study that highlights where this rapidly evolving field is headed.  Shorter discussions include heart disease at a young age, why so many patients fail to reach blood pressure treatment goals, aspirin use one year after AFib ablation, skeletal muscle as an endothelial stabilizer, and why exercise variety may be one of the most powerful risk reducers we have.  Thanks to WellBean for sponsoring the show. Save on their delicious bean-based products at wellbean.life with code DrKahn15.  Dr. Kahn will also be leading a free online seminar on cholesterol on February 17, 2026 at 7 PM EST with Forks Over Knives. Register HERE.

Send us a textDr. H. Jackson Downey sits down with MedEvidence!™ to give the low-down on keeping your lipoprotein(a) numbers down. Lipoprotein little a, also called Lp(a), is a really, really, really, really, really bad cholesterol that is genetically determined, meaning exercise and diet don't help lower the numbers. Instead, Dr. Downey explains, clinical trials are looking into investigational medications for this bad type of cholesterol. Dr. Downey describes the ins and outs of Lp(a) and how clinical research is our best bet for solutions to this dangerous cholesterol.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

On this podcast episode, I discuss important practice pearls and important test prep information about statins. Statins are cornerstone agents for ASCVD risk reduction, so test questions often focus on indication, intensity, and monitoring. Health care professionals should quickly identify statin intensity: high-intensity therapy (atorvastatin 40–80 mg, rosuvastatin 20–40 mg) lowers LDL by ~50% and is indicated for patients with clinical ASCVD, LDL ≥190 mg/dL, or high-risk diabetes patients age 40–75. Moderate-intensity statins (e.g., atorvastatin 10–20 mg, simvastatin 20–40 mg) are commonly tested for primary prevention. Statin-associated muscle symptoms range from myalgias (most common, normal CK) to rare but serious rhabdomyolysis (marked CK elevation and AKI). Risk factors include high doses, advanced age, hypothyroidism, drug interactions, and renal impairment. If muscle symptoms occur, stopping the statin, ruling out secondary causes (like hypothyroidism), and rechallenging with a lower dose or different statin is often the correct clinical approach. Drug interactions and statin selection frequently separate good from great test-takers. Lipophilic statins (simvastatin, atorvastatin, lovastatin) are more prone to muscle effects and CYP3A4 interactions, while hydrophilic statins (pravastatin, rosuvastatin) are preferred in patients with prior intolerance or complex drug regimens. Grapefruit juice, strong CYP3A4 inhibitors, and certain calcium channel blockers raise simvastatin levels—often prompting dose limits or avoidance on exams. If LDL goals aren’t met, adding ezetimibe or a PCSK9 inhibitor is the next evidence-based step. Be sure to check out our free Top 200 study guide – a 31 page PDF that is yours for FREE! Support The Podcast and Check Out These Amazing Resources! NAPLEX Study Materials BCPS Study Materials BCACP Study Materials BCGP Study Materials BCMTMS Study Materials Meded101 Guide to Nursing Pharmacology (Amazon Highly Rated) Guide to Drug Food Interactions (Amazon Best Seller) Pharmacy Technician Study Guide by Meded101

A dislipidemia deixou de ser um tema restrito a “colesterol alto” e a Diretriz Brasileira de 2025 veio para deixar bem claro que o foco é prevenção da aterosclerose e suas repercussões em desfechos cardiovasculares!No DozeCast #208, Victor Bemfica e Diandro Mota discutem os principais destaques da nova diretriz e o que, de fato, muda na prática clínica.Falamos sobre:• Atualizações na estratificação de risco e tomada de decisão clínica• Metas lipídicas e marcadores adicionais (não-HDL, ApoB, Lp(a))• Estratégias de tratamento: intensificação precoce e terapias combinadas quando indicado• Papel das terapias hipolipemiantes modernas: anti-PCSK9, inclisiran, ácido bempedoico, entre outras • Condutas em populações específicas (diabetes, DRC, idosos e alto risco)

Doug Reynolds welcomes listeners back to the LowCarbUSA® Podcast with a guest who works in one of the most specialized—and most misunderstood—corners of cardiovascular medicine: the heart's electrical system.  Dr. David Nabert is an electrophysiologist ("EP" doctor), focused on heart rhythm disorders, and he's one of the featured speakers at the Boca Symposium for Metabolic Health (January 23–25)—including the event's full day-plus dedicated to cardiovascular conditions. What gives this episode its pull is the combination of clinical depth and lived experience. David isn't just talking about rhythm problems from a textbook perspective—he's explaining how his own curiosity about metabolic health evolved, what shifted when he started questioning conventional assumptions, and why those questions matter for real patients in the real world. David describes how his entry point into metabolic health didn't begin in a clinic—it began with a random Google search. In 2021, while looking up a cardiology formula, he accidentally landed on a Nina Teicholz talk at the Cato Institute. "I started to watch it, and all of a sudden, an hour and a half passed," he says—one of those moments where interest turns into momentum. He listened to Teicholz's book, The Big Fat Surprise, then began searching for more voices in the low-carb space and quickly reconnected with familiar names, including Dr. Robert Cywes and Dr. Eric Westman (both will also be presenting in Boca), whom he calls mentors. That exploration ultimately led him to the Society of Metabolic Health Practitioners (The SMHP) and, importantly, a willingness to test ideas on himself. David is candid about his own weight journey. He describes a time when a body mass index under 25 felt "skinny" to him, and he's open about losing weight, regaining some after a series of hip surgeries, and continuing to work on it. What ultimately shifted, though, wasn't just the number on the scale—it was how he began to rethink what "doing everything right" actually means. For years, he approached weight loss the way many clinicians were trained to: low-fat, high willpower, endure the hunger. He describes his old strategy bluntly: "The only way I had lost weight… was by doing protein sparing modified fast… I was just eating almost no fat." Predictably, it wasn't sustainable. When he later shifted to a lower-carb, higher-fat approach—"bacon, eggs, hamburger"—he was "amazed at how quickly I started to lose weight," and he began seeing changes in markers that traditional cardiology often de-emphasizes. After stopping long-term statin therapy (which he had been on for 25 years), he saw his LDL return to roughly where it had been earlier in life, but other changes caught his attention: triglycerides dropped to the lowest he'd ever seen, HDL improved, and fasting insulin improved as well. Just as meaningful were the changes he felt: "Every 10 or 20 pounds I lost, my hips got better," he says, attributing it not only to less load, but "also part of it was less inflammation." From there, the episode moves into the heart of why David is speaking during the cardiovascular-focused programming in Boca: rhythm, electricity, and the surprising overlap between conditions that seem unrelated—like seizures and arrhythmias. David explains that early ketogenic diet research in the 1920s focused on refractory seizures, and he argues the connection matters because many antiarrhythmic drugs and antiseizure drugs overlap mechanistically. In his view, these aren't separate worlds. "Treating seizures or treating cardiac arrhythmias is basically two faces of the same coin," he says—and that opens a practical question: if ketosis can help reduce seizures, might it also influence certain rhythm symptoms? He shares a striking clinical example that stuck with him: a former submariner with PTSD and episodes of fast heart rates who said, "I know when I'm… ketogenic… when I fall off the wagon… then I start having palpitations and fast heart rates." David later learned the patient was experiencing atrial fibrillation, and while he's careful not to overpromise, he describes a pattern he's observed: in earlier stages of rhythm problems, being in a ketogenic state may reduce symptoms and potentially slow progression for some people. "It doesn't cure atrial fibrillation," he emphasizes, but he's seen ketosis "improves symptoms," not only in AFib, but in other rhythm issues like SVT and PVCs—especially early on. From there, David widens the frame to what he's seeing in younger patients—particularly young women—showing up with palpitations, rapid heart rate, anxiety, and signs of metabolic dysfunction even when they don't "look" unhealthy by BMI alone. "Only 90% of them are metabolically unhealthy," he says, describing a familiar cluster: A1C not quite normal, resting heart rates high, daytime heart rates that shouldn't be running 100–120, and a nervous system dialed up in what he calls a "hyper adrenergic state." The mainstream response is often medication—beta blockers, for example—but David argues metabolic context matters, and he's exploring how nutritional strategies (including ketosis, sometimes even supplemental ketones) may reduce symptom burden in certain cases. He also discusses POTS (Postural Orthostatic Tachycardia Syndrome), noting it can be associated with viral infections and has become more common since "the bad virus we had five years ago." Again, he's measured in his claims: ketosis isn't a cure, but he's seen it help reduce symptoms in select patients who have tried many other standard approaches first. The second half of the conversation touches on medications and the tension between "lower the number" cardiology and whole-person outcomes. David brings up PCSK9 inhibitors and recalls being troubled by early data patterns: "You were less likely to die from that, but you're more likely to die from cancer or infection… And… the overall mortality was the same." That line of thinking captures what pushed him toward metabolic health: a concern that focusing on a single marker can obscure the bigger picture of risk, resilience, and long-term outcomes. He also discusses SGLT2 inhibitors (like Jardiance and Farxiga) as potentially useful tools—especially in heart failure and diabetes—while stressing the importance of monitoring and hydration. In a moment that captures both his clinical caution and his enthusiasm for empowered patients, he tells people who go low carb on these meds to "get a Keto Mojo to check your ketone levels," because the goal is to use tools intelligently, not blindly. As the episode closes, Doug returns to the bigger mission behind the upcoming Boca program: helping attendees develop a confident, educated response to the most common fear tactic people face when they change their diet—LDL, heart attacks, and the assumption that low carb automatically means danger. Doug notes there are still "so few that really do get it and support it and talk about it," which is exactly why the cardiovascular-focused day-plus at the Boca Symposium for Metabolic Health (January 23–25) matters. David, for his part, is grateful to be part of it—and to be healthy enough to show up differently than last time. He reminds Doug that at previous events he was "either walking with one or two canes," but now, "I'm actually not going to run up on the stage, but I'll be moving pretty quickly." That moment captures the heart of the episode: metabolic health isn't theoretical. It's lived. And in Boca, that lived experience meets serious clinical discussion—especially for anyone trying to better understand cardiovascular risk, rhythm disorders, and the metabolic foundations that too often go unaddressed. If this conversation sparks your curiosity, the next step is obvious: join the community in Boca January 23–25 and immerse yourself in a day and a half of cardiovascular-focused talks designed to help you think more clearly, speak more confidently, and act more effectively—whether you're a clinician, a patient, or someone trying to help the people you love. Learn more about the Boca Symposium and register here.

Send us a textDr. Christie M. Ballantyne, MD is a Cardiologist and is one of the nation's foremost experts on lipids, atherosclerosis and heart disease prevention. He holds many leadership positions at Baylor College of Medicine ( https://www.bcm.edu/people-search/christie-ballantyne-17846 ), including director of the Center for Cardiometabolic Disease Prevention, co-director of the Lipid Metabolism and Atherosclerosis Clinic, and chief of the Section of Cardiology. With over 1000 publications in the area of atherosclerosis, lipids, and inflammation, Dr. Ballantyne's research on heart disease prevention has led him to become an established investigator for the American Heart Association and the recipient of continuous funding from the National Institutes of Health with a core focus on in basic research of leukocyte–endothelial interactions, translational research in biomarkers, and clinical trials.Dr. Ballantyne's many accomplishments have included being elected as Fellow of the American Association for the Advancement of Science, the American Society of Clinical Investigation, and the Association of American Physicians. In 2012, he received the American College of Cardiology Distinguished Scientist Award (Basic Domain). In 2014 and 2015, Thomson Reuters recognized Dr. Ballantyne as one of “The World's Most Influential Scientific Minds.” Clarivate Analytics, Web of Science, named Dr. Ballantyne as a “Highly Cited Researcher” 2017-2022 in the top 1% of researchers most cited. In 2019, Dr. Ballantyne was awarded the Baylor College of Medicine Michael E. DeBakey, M.D., Excellence in Research Award. His research in biomarkers has led to the FDA approval of 2 biomarkers for cardiovascular risk prediction, and he has played a prominent role in the development and FDA approval of new therapies for treatment of lipids.Dr. Ballantyne also serves on the Editorial Board for Circulation and the Journal of the American College of Cardiology. He received his MD from Baylor College of Medicine with internal medicine residency at The University of Texas Southwestern Medical School and cardiology fellowship at Baylor College of Medicine and an AHA fellowship at the Howard Hughes Medical Institute and Institute for Molecular Genetics at Baylor.Dr. Alexander Tal, MD is an accomplished and recently retired board-certified Endocrinologist ( https://www.doximity.com/pub/alexander-tal-md ) with extensive training from institutions like Baylor College of Medicine, East Tennessee State University/Quillen College of Medicine, Mount Sinai Hospital Medical Center of Chicago and Tel Aviv University Sackler, where he specialized in Diabetes, Metabolism, and Geriatric Medicine, and held Fellow status with the American Association of Clinical Endocrinology, treating various hormonal conditions.Important Episode Link - Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial - https://www.merck.com/news/mercks-enlicitide-decanoate-an-investigational-oral-pcsk9-inhibitor-significantly-reduced-ldl-c-in-phase-3-coralreef-lipids-trial/#ChristieBallantyne #Cardiologist #Lipids #Atherosclerosis #HeartDiseasePrevention #BaylorCollegeOfMedicine #CardiometabolicDisease #LipidMetabolism #Cardiology #AlexanderTal #Endocrinologist #Diabetes #Metabolism #GeriatricMedicine #Merck #Enlicitide #OralPCSK9Inhibitor #Statins #Ezetimibe #Hypercholesterolemia #apoB #Lpa #Lipoproteins #Healthspan #Longevity #Aging #STEM #Innovation #Science #Technology #Research #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcastSupport the show

This week, Brent speaks with his personal physician, Dr. Todd Dorfman, for an update on his own health journey. Using Brent as a real-world case study, they walk through the discovery of an anomalous coronary artery, the risks and benefits of advanced cardiac diagnostics, and why more testing isn't always better. The conversation then shifts to prevention. Dr. Dorfman shares how he thinks about cholesterol, ApoB, Alzheimer's risk, statins, PCSK9 inhibitors, GLP-1 drugs, and other emerging therapies when you don't have disease but want to stay ahead of it. As always, Dr. Dorfman is a wonderful guest. Hope you enjoy.

Peripheral artery disease has been called the ‘silent circulatory crisis'—affecting millions, limiting mobility, and quietly raising the risk of heart attack, stroke, and limb loss. For decades, treatment focused on walking programs, aspirin, and sometimes a stent or bypass. But today, the landscape is changing. From PCSK9 inhibitors that drive cholesterol to record lows, to GLP-1 agonists like semaglutide improving walking distance, to novel antithrombotic strategies that balance bleeding and clotting—PAD care is entering a new era. In this episode, we'll explore the breakthroughs, the evidence behind them, and what they mean for patients who just want to keep moving forward." Hosted by the University of Michigan Department of Vascular Surgery: - Robert Beaulieu, Program Director - Frank Davis, Assistant Professor of Surgery - Luciano Delbono, PGY-5 House Officer - Andrew Huang, PGY-4 House Officer - Carolyn Judge, PGY-2 House Officer Learning objectives:  1.  Describe the current evidence-based recommendations for multifactorial medical management of peripheral artery disease (PAD), including lipid, glycemic, and antithrombotic strategies per 2024 SVS/AHA guidelines.  2. Interpret the clinical implications of the FOURIER trial regarding the role of PCSK9 inhibition in reducing cardiovascular events in patients with atherosclerotic disease, including PAD.  3.  Evaluate the emerging role of GLP-1 receptor agonists, such as semaglutide, in improving walking performance and quality of life among patients with diabetic PAD based on findings from the STRIDE trial. Sponsor URL: https://www.goremedical.com/ References:  H. L. Gornik et al., “2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease,” JACC, vol. 83, no. 24, pp. 2497–2604, June 2024, doi: 10.1016/j.jacc.2024.02.013. L. Mazzolai et al., “2024 ESC Guidelines for the management of peripheral arterial and aortic diseases: Developed by the task force on the management of peripheral arterial and aortic diseases of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN), and the European Society of Vascular Medicine (ESVM),” Eur Heart J, vol. 45, no. 36, pp. 3538–3700, Sept. 2024, doi: 10.1093/eurheartj/ehae179. https://pubmed.ncbi.nlm.nih.gov/40169145/ M. S. Sabatine et al., “Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease,” N Engl J Med, vol. 376, no. 18, pp. 1713–1722, May 2017, doi: 10.1056/NEJMoa1615664. https://pubmed.ncbi.nlm.nih.gov/28304224/ M. P. Bonaca et al., “Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial,” Lancet, vol. 405, no. 10489, pp. 1580–1593, May 2025, doi: 10.1016/S0140-6736(25)00509-4. https://pubmed.ncbi.nlm.nih.gov/40169145/ N. E. Hubbard, D. Lim, and K. L. Erickson, “Beef tallow increases the potency of conjugated linoleic acid in the reduction of mouse mammary tumor metastasis,” J Nutr, vol. 136, no. 1, pp. 88–93, Jan. 2006, doi: 10.1093/jn/136.1.88. https://pubmed.ncbi.nlm.nih.gov/16365064/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

CME credits: 0.25 Valid until: 30-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/earlier-action-lasting-impact-closing-the-ldl-c-gap-in-patients-without-a-prior-mace/39957/ This program explores evolving strategies for low-density lipoprotein cholesterol (LDL-C) management in patients at high cardiovascular (CV) risk who have not yet experienced a myocardial infarction or stroke. Drs. Bohula and Leiter discuss unmet needs, shifting LDL-C targets, and emerging treatment strategies, including PCSK9 inhibitors and results from the VESALIUS-CV trial. The conversation highlights how early, intensive LDL reduction can meaningfully lower the risk of first CV events. Practical guidance is shared on risk assessment, statin optimization, evaluating and managing statin intolerance, and the use of combination lipid-lowering therapy.=

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving deep into the latest breakthroughs, regulatory updates, and industry trends shaping the future of healthcare.Let's start with Johnson & Johnson's recent achievement in precision oncology. They've secured a second FDA approval for Akeega, a combination therapy that merges J&J's Zytiga with GSK's Zejula. This innovative approach targets BRCA2-mutated metastatic castration-sensitive prostate cancer, marking a significant advancement in personalized medicine. This approval not only highlights the progress in tailored treatment strategies but also sets a new benchmark for therapeutic innovation in this particular cancer subset.Moving on to cardiovascular health, Cincinnati's LIB Therapeutics has introduced Lerochol, a third-generation PCSK9 inhibitor designed to lower cholesterol. Unlike its predecessors, Lerochol offers simplified administration, potentially improving patient adherence and outcomes. This approval is part of a broader effort to refine lipid-lowering therapies and better address cardiovascular diseases.In a groundbreaking development for heart rhythm disorders, Milestone Pharmaceuticals has received FDA approval for Cardamyst, a nasal spray that patients can self-administer to manage paroxysmal supraventricular tachycardia (PSVT). This novel treatment option empowers patients with an on-demand solution to control their heart rhythms, significantly enhancing their quality of life.Turning to infectious diseases, Innoviva's Nuzolvence has been approved as a much-needed new treatment for gonorrhea, the first in over three decades following GSK's Blujepa. This marks an essential step forward in combating antibiotic-resistant sexually transmitted infections and highlights the urgency of developing new antimicrobial agents.However, not all ventures have met with success. Argenx recently halted studies of its drug Vyvgart in thyroid eye disease after disappointing trial results. This decision underscores the inherent challenges and risks involved in drug development, particularly when tackling complex autoimmune conditions.Sanofi has faced its own hurdles with Tolebrutinib after experiencing both FDA delays and trial misses in non-relapsing secondary progressive multiple sclerosis. These setbacks emphasize the intricacies of bringing innovative therapies to market and the critical importance of robust clinical trial design and regulatory strategy.Strategic collaborations are also playing a pivotal role in the industry. Adaptive Biotechnologies has partnered with Pfizer to leverage its T-cell receptor discovery technology. Meanwhile, Dren Bio is expanding its collaboration with Sanofi to develop next-generation B-cell depleting therapies for autoimmune diseases. These alliances reflect an increasing trend towards collaborative innovation to harness cutting-edge technologies.Another strategic move comes from Sobi, which has acquired Arthrosi Therapeutics for $950 million to bolster its portfolio with phase 3 gout treatments. This acquisition bypasses traditional IPO routes and showcases evolving deal-making strategies within biopharma.In another exciting development, Kyverna Therapeutics is on the verge of securing the first-in-class CAR-T therapy approval for autoimmune diseases following promising trial results with its CD19 agent. This could herald a new era in autoimmune disease management through cellular therapies.In regulatory news beyond pharmaceuticals, former President Donald Trump signed an executive order establishing a unified federal framework for artificial intelligence (AI). This aims to streamline AI regulation across states and could accelerate AI integration into various sectors, including healthcare.These developments collectively represent pivotal moments in the pharmaceutical and Support the show

I am honored to have Dr. Tom Dayspring join me again today for another AMA session. He and I have done eight podcasts before, and this is a continuation of our last Ask Me Anything episode.  Dr Dayspring is an esteemed expert on internal medicine and clinical lipidology. He is likely one of the most influential worldwide lipid experts, so I am thrilled to have him back with me to dive into various topics related to listener questions, including the impact of hormone replacement therapy on lipid changes, methods of administration, and why bioidentical hormone replacement therapy is preferable for managing both menopausal symptoms and lipid health. We discuss medications, including PCSK9 inhibitors and GLP-1s, as well as intermittent fasting, lipids, and cardiovascular disease risk. We also examine how heart disease develops gradually, over time, the impact of stress and lifestyle, and Dr. Dayspring shares the labs he recommends beyond traditional lipids, ApoB, and LpA. In our discussion, Dr. Dayspring noted that he was not in a position to speak about GLP-1 therapies or microdosing. Since I received many questions from listeners on those topics, I will host a future solo AMA to address some of their concerns. Today's conversation with Dr. Tom Dayspring is truly invaluable, and I trust you will walk away with valuable insights you can share with your healthcare providers. We created a PDF - cynthiathurlow.com/lipids -  specifically for listeners that outlines key labs to discuss with your providers and questions to ask them to help you advocate for your own health and your family members' health. IN THIS EPISODE, YOU WILL LEARN: Why being physically fit does not always eliminate the risk of heart problems arising How ApoB and cholesterol contribute to heart disease over decades Why the early testing of risk factors is essential How chronic stress increases the risk of heart disease  How high cortisol affects insulin sensitivity and glucose regulation How stress impacts endothelial and nitric oxide function The link between low Omega-3 levels and heart problems How insulin resistance degrades heart health How high homocysteine levels can impair endothelial function and contribute to cardiovascular problems Connect with Cynthia Thurlow   Follow on⁠ X⁠,⁠ Instagram⁠ &⁠ LinkedIn⁠ Check out Cynthia's⁠ website⁠ Submit your questions to support@cynthiathurlow.com Join other like-minded women in a supportive, nurturing community ⁠(The Midlife Pause/Cynthia Thurlow⁠)⁠ ⁠ Cynthia's⁠ Menopause Gut Book⁠ is on presale now! Cynthia's⁠ Intermittent Fasting Transformation⁠ Book ⁠The Midlife Pause supplement line⁠ Connect with Dr. Thomas Dayspring On X (@DrLipid) On LinkedIn

Updates on coffee and AFib, a polypill approach for HFrEF, the first oral PCSK9 inhibitor, vitamin D supplementation for secondary prevention, and more: Joanna Chikwe, MD, chair of the American Heart Association's Scientific Sessions conference and of the Department of Cardiac Surgery in the Smidt Heart Institute at Cedars-Sinai Medical Center, shares clinical research highlights from the recent meeting. Related Content: Coffee and AFib, Oral PCSK9 Drugs, an HFrEF Polypill, and Vitamin D Post-MI—Highlights From AHA 2025

A long-term Framingham Heart Study analysis shows that regular physical activity beginning in midlife and continuing into older age significantly lowers the risk of dementia, including Alzheimer disease, with the most active individuals experiencing roughly 40–45% risk reduction. A phase 3 trial of the first oral PCSK9 inhibitor, enlicitide, demonstrated substantial LDL-C and apoB reductions in patients with heterozygous familial hypercholesterolemia already on statins, offering a well-tolerated oral option that helps most patients reach guideline targets. Finally, a large U.S. cohort study revealed persistent under-treatment of chronic hepatitis B—especially among women and non-Asian racial groups—highlighting the need for standardized assessment and timely antiviral therapy to close these gaps.

New NEJM insights on asymptomatic carotid stenosis

This week, Dr. Kahn provides details on presentations just made and published at the annual scientific meeting of the American Heart Association in New Orleans. Topics include a polypill for heart failure, coffee for atrial fibrillation, an oral PCSK9 inhibitor, beta-blockers after heart attacks, gene editing to lower cholesterol, and the use of PCSK9 inhibitors (Repatha) in a randomized trial of patients at risk for heart attack and stroke.  Dr. Kahn also reviews the role of lycopene in preventing prostate cancer (think tomatoes), colchicine in heart patients, the power of combining statins with ezetimibe, earlier mitral valve repairs, and new data suggesting that drugs like tadalafil (Cialis) may reduce the risk of death and dementia.  Dr. Kahn thanks tryauri.com/drkahn for their support and discount for listeners of Heart Doc VIP.

Program notes:0:50 Fish oil supplements and hemodialysis1:50 1200 individuals to fish oil or not2:50 Needs another study3:11 PCSK9 inhibitor in people without MI or stroke4:13 3- or 4-point MACE5:11 Getting LDL down helps6:11 Addition of more than one oral agent6:50 Right therapy for afib and a stent7:50 Noninferiority trial8:50 After 12 months single agent works9:27 Anticoagulation after afib tx10:30 Low primary safety outcomes11:25 96% won't have a stroke12:16 End

Send us a textGood morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of groundbreaking changes and innovations reshaping the landscape of drug development, clinical trials, and regulatory affairs.In a major move, Pfizer has successfully outbid Novo Nordisk to acquire Metsera for $10 billion. This strategic acquisition aims to bolster Pfizer's presence in the obesity treatment market by leveraging Metsera's GLP-1 receptor agonist technology. This acquisition underscores the continuing trend of consolidation within the pharmaceutical industry, enhancing competitive market positioning and reflecting a broader quest for novel therapeutic solutions.Eli Lilly has entered into a $1.2 billion collaboration with Sangenebio to advance RNA interference (RNAi) therapeutics targeting metabolic diseases. This partnership marks a pivotal shift towards utilizing RNAi technology to silence disease-causing genes, representing significant progress in metabolic disease treatment. The focus on innovative delivery mechanisms and targeted interventions is critical for accelerating drug development and enhancing therapeutic efficacy.Onchilles Pharma's recent Series A1 funding round, securing $25 million, marks a notable advancement in oncology therapeutics. The company's focus on dual-action cancer biologics targeting the ELANE pathway offers promising insights into immune activation in solid tumors. This investment exemplifies the growing interest in biologic therapies that provide targeted cancer treatments, potentially leading to more effective options for patients.Regulatory advancements are also making headlines. Chongqing Precision Biotech has received approval for Pujiolunxi, a treatment for pediatric relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), broadening therapeutic options for this challenging pediatric condition. Furthermore, Alembic Pharmaceuticals' generic version of Dasatinib tablets has gained FDA approval for Philadelphia chromosome-positive chronic myeloid leukemia, increasing accessibility to treatment.Several promising clinical trial results have emerged recently. Summit Therapeutics and Akeso Biopharma's Ivonescimab showed a 26% overall survival benefit in phase 3 trials for non-small-cell lung cancer. The potential of bispecific antibodies in combination therapies is gaining attention for its efficacy in difficult-to-treat cancers. Additionally, Regeneron's Dupixent has achieved phase 3 success in treating allergic fungal rhinosinusitis, reinforcing its role as a versatile treatment option across various inflammatory diseases.Advancements in cardiovascular therapeutics also continue to unfold. Merck & Co.'s Enlicitide Decanoate demonstrated over 50% LDL cholesterol reduction in a phase 3 study focused on atherosclerotic cardiovascular disease through PCSK9 inhibition. AstraZeneca's Baxdrostat showed significant blood pressure reduction in trials targeting treatment-resistant hypertension, highlighting the potential impact of aldosterone synthase inhibitors on cardiovascular health.The investment landscape remains robust with substantial fundraising activities such as Elephas Biosciences' $40 million Series B-2 for commercializing their live tumor profiling platform and Iambic's over $100 million series focused on AI-driven drug discovery. These investments underscore the industry's commitment to integrating advanced technologies like AI and live tumor profiling to enhance precision medicine capabilities.FDA regulatory updates are pivotal as well, notably with the decision to lift warning labels from hormone replacement therapy (HRT) products following an expert review that found previous warnings were based on misinformation regaSupport the show

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In today's rapidly evolving landscape, we witness significant strides shaping the future of drug development, patient care, and global market dynamics.Merck & Co. has made a notable advancement in cholesterol management with a PCSK9-targeted pill. This pill has achieved reductions in low-density lipoprotein cholesterol (LDL-C) comparable to existing injectable therapies. Such innovation represents a significant step forward by potentially offering a more convenient oral alternative for patients. The development underscores the industry's ongoing efforts to enhance patient compliance and therapeutic outcomes through novel drug delivery mechanisms.In a strategic corporate move, Pfizer has successfully acquired Metsera, an obesity biotech company, for a substantial $10 billion. This acquisition, which followed an intense bidding war with Novo Nordisk, exemplifies Pfizer's aggressive expansion in the obesity treatment market—a growing global health challenge. The strategic buyout positions Pfizer to leverage Metsera's expertise, potentially accelerating the development and commercialization of innovative obesity treatments.Meanwhile, Novo Nordisk is enhancing its presence in India by partnering with Emcure Pharmaceuticals to expand access to Wegovy, its weight-loss treatment. This collaboration is particularly significant given India's escalating obesity rates and highlights the importance of regional partnerships in enhancing drug accessibility and addressing public health issues.Regulatory developments continue to influence industry dynamics as well. The FDA has postponed its decision on expanding Rhythm Pharmaceuticals' Imcivree for additional indications. These regulatory delays highlight the complexities and unpredictabilities inherent in drug approval processes, underscoring the need for companies to strategically navigate these challenges.Regeneron and AstraZeneca have reported clinical trial successes with their respective anti-inflammatory drugs, Dupixent and Fasenra. These positive outcomes were showcased at the American College of Allergy, Asthma, and Immunology's annual meeting, bolstering the companies' aspirations for FDA approvals. Successful clinical outcomes not only pave the way for expanded therapeutic options but also demonstrate the industry's commitment to addressing complex inflammatory conditions.October has seen a surge in TV advertising spending, led by Johnson & Johnson's campaign for Tremfya. The campaign highlights the power of patient community engagement in bringing attention to conditions like inflammatory bowel disease (IBD), emphasizing how patient advocacy can reduce isolation among sufferers.In oncology, Cogent Biosciences is on track for an FDA submission following successful phase 3 trials of its cancer asset bezuclastinib. This development illustrates the critical role of rigorous clinical research in advancing oncology treatments and potentially improving patient outcomes.Turning our attention to technological frontiers within pharmaceutical R&D, Eli Lilly has been particularly active in cementing its commitment to artificial intelligence (AI) and gene therapy through several strategic collaborations. The company has entered into a $100 million-plus research agreement with Insilico Medicine to leverage AI for drug discovery. This partnership aims to expedite the identification of novel therapeutic targets and enhance drug development efficiency—a reflection of a broader industry trend towards integrating AI into pharmaceutical processes.Additionally, Lilly has made a notable move in gene therapy by acquiring rights from MeiraGTx for a retinal disease therapy that has shown Support the show

Special Edition of the JAMA Editor's Summary featuring JAMA Network articles published at the 2025 AHA Scientific Sessions. Hosted by JAMA Executive Editor Gregory Curfman, MD, JAMA Senior Editor Philip Greenland, MD, and JAMA Cardiology Editor Robert O. Bonow, MD, MS. Related Content: Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia Liberal or Restrictive Postoperative Transfusion in Patients at High Cardiac Risk Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation DASH-Patterned Groceries and Effects on Blood Pressure Coronary Computed Tomography Angiography in Prediction of First Coronary Events Metformin to Improve Walking Performance in Lower Extremity Peripheral Artery Disease Physical Activity and Cardiovascular Outcomes in Phenotype-Negative Cardiomyopathy Variant Carriers Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy Atorvastatin and Aortic Stiffness During Anthracycline-Based Chemotherapy Clonal Hematopoiesis and Incident Heart Failure Chronic Kidney Disease Prevalence and Awareness Among US Adults Cardiotoxic Effects of Antibody Drug Conjugates vs Standard Chemotherapy in ERBB2-Positive Advanced Breast Cancer Prenatal Care and Perinatal Regionalization for Congenital Heart Defects Lifestyle Intervention for Sustained Remission of Metabolic Syndrome

CME credits: 0.50 Valid until: 02-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/crossing-boundaries-cetp-inhibitors-and-the-next-frontier-in-lipid-control/33025/ Cardiologists explore advances in lipid management, from statin intolerance to emerging lipid targets like ApoB and non-HDL cholesterol. The series emphasizes the pivotal role of combination therapy—including ezetimibe, PCSK9 inhibitors, and novel agents such as bempedoic acid and inclisiran—in achieving LDL-C goals. Special focus is given to cholesteryl ester transfer protein (CETP) inhibition as a breakthrough strategy, with trials showing potent LDL-C reduction, improved goal attainment, and promising effects on cognition and inflammation. Together, these discussions highlight how CETP inhibitors may redefine future cardiovascular therapy.=

We have the second episode in a series of conversations with Dr. Thomas Dayspring today.  The esteemed Dr. Dayspring is an expert on internal medicine and clinical lipidology. In this episode, we continue with our last conversation, diving into Lp(a) and the influences of gender, race, and menopause. We explain how estrogen is a PCSK9 inhibitor and explore the significance of brain health and risks for dementia. We tackle cholesterol synthesis and discuss the side effects of statins, clarifying who is most susceptible to their impact on the brain. We also examine the significance of the desmosterol biomarker, highlighting the level to aim for, especially when making decisions regarding cholesterol medications, and we answer one question from a listener.  You may want to listen to this insightful conversation with the renowned Dr. Dayspring more than once. He has graciously agreed to return and film additional episodes, where we will dive into more questions from listeners.  IN THIS EPISODE, YOU WILL LEARN: Why Lp(a) is like a wolf in sheep's clothing for many individuals How Lp(a) levels are higher in African Americans and women, especially after menopause  Dr. Dayspring highlights that Lp(a) particles are even more pro-inflammatory than LDL particles How PCSK9 inhibitors are the only drugs that significantly reduce Lp(a) Why do women have a higher risk of dementia than men? Dr. Dayspring explains ApoE as the key lipoprotein for brain cholesterol transport. How statins cross the blood-brain barrier to lower brain cholesterol Why desmosterol levels matter New therapies that can lower ApoB and Lp(a) Why imaging is essential for menopausal women with elevated ApoB and Lp(a) Connect with Cynthia Thurlow   Follow on X, Instagram & LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com Connect with Dr. Thomas Dayspring On X (@Drlipid) On LinkedIn Journal Article: Atherosclerosis: Non-genetic influences on lipoprotein(a) concentrations  Journal of the American Heart Association: Trajectories of Blood Lipid Profiles in Midlife Women: Does Menopause Matter?

In this Healthed lecture, Dr Robert Hungerford discusses the latest evidence-based recommendation to lower LDL-C targets even further in various at-risk groups, as well as the most effective means of reaching those targets in real-world Australian clinical practice. He will also present the value of combination therapy, the value of starting combination early, the role of the newer PCSK9 inhibitors and their current PBS eligibility criteria.See omnystudio.com/listener for privacy information.

Efficacy And Safety of AZD0780, An Oral Small Molecule PCSK9 Inhibitor For Treatment Of Hypercholesterolemia: Results From A Ph2b Randomized Placebo-controlled Clinical Trial

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Robert F. Kennedy Jr.'s removal of all members of the CDC's Advisory Committee on Immunization Practices has raised concerns about the upcoming meeting later this month. Analysts fear that the committee may become more sympathetic to anti-vaccine viewpoints. In other news, Merck has received FDA approval for an RSV antibody, Gilead has paused five HIV trials but Lenacapavir remains safe, and the FDA has reinstated a previously disbanded generic drug policy panel. Gilead has expressed faith in its HIV combo therapy and pledged to work with regulators to resolve the hold on its trials. In vitro cell research is focused on discovering interventions to slow aging and prevent age-related diseases.Kennedy's vaccine campaign is seen as breeding more distrust, while Metsera's weight loss injection has shown positive results. Merck is moving forward with an oral PCSK9 inhibitor. Thank you for tuning in to Pharma and Biotech daily for the latest updates in the pharmaceutical and biotechnology industries.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Metsera's new long-acting amylin injection, met-233i, has shown promising weight loss results over eight months, leading to a rise in shares. Meanwhile, CDC vaccine advisors are either being pushed out or leaving their positions. Other top stories include Sirna's expansion beyond the liver, Keros returning $375 million to investors, and ACIP members receiving termination notices. In vitro cell research is focused on slowing aging and preventing age-related diseases. Updates on Merck's oral PCSK9 inhibitor, Sanofi and Regeneron's Dupixent effectiveness, and Avidity's muscular dystrophy drug are also highlighted.The expansion of RNA therapeutics is discussed, with multiple companies aiming to target small interfering RNA to various organs by 2030. Uniqure's regulatory progress in developing a gene therapy for Huntington's disease has sparked optimism, although past disappointments for patients are noted. Perspective Therapeutics presents new data on neuroendocrine tumor treatment at ASCO25. Concerns about RFK Jr.'s vaccine campaign and its potential to increase distrust in vaccines are raised in the editorial. Cancer news, cell and gene therapy updates, upcoming events, job listings, and a call for reader suggestions on coverage topics are also covered.

In this special JACC lipid-focused issue, Dr. Valentin Fuster explores groundbreaking global research on lipoprotein(a), its complex role in cardiovascular disease across populations, and the promising future of targeted therapies. From massive Chinese cohort studies to a novel oral PCSK9 inhibitor trial, this episode highlights the frontlines of lipid science shaping tomorrow's heart health.

This month on Episode 72 of Discover CircRes, host Cindy St. Hilaire highlights four articles featured in the April 25th and May 9th issues of Circulation Research. This Episode also includes a discussion with Dr Sarah Costantino and Dr Francesco Paneni from University Hospital Zurich about their study, Chromatin Rewiring by SETD2 Drives Lipotoxic Injury in Cardiometabolic HFpEF     Article highlights: Laudette, et al. PCSK9 and Mitochondrial Cholesterol in Heart Yang, et al. Srsf3 Limits AS by Lengthening 3′ UTRs of mtARSs Li, et al.  CircCDYL Contributes to Cardiac Hypertrophy Zhakeer, et al. Treg Cells Regulate Pulmonary Venous Remodeling

If you've been anywhere near health optimization circles, you already know Ben Greenfield as a NYT bestselling author, former Ironman triathlete, coach, one of the OGs of biohacking. Today, he's my guest on the Longevity podcast.   What we discuss: Ben's new home, cold exposure, and microdosing cryotherapy ... 00:06 Writing, updating, and revising “Boundless” ... 00:09 Key updates: Self-quantification, longevity, new detox protocols ... 00:12 High-tech blood filtration and its impact ... 00:15 Daily detox strategies: Lymphatic movement, sauna, exercise ... 00:17 Ben's evolution: From strict keto to Mediterranean-style eating ... 00:21 Genetics, ancestry, and personalized nutrition lessons ... 00:23 Impact of endurance training, hormone and gut issues, recovery via flexible dieting ... 00:27 Addressing high coronary plaque: Statins, PCSK9 inhibitors, supplementation ... 00:35 Tracking heart health non-invasively (CIMT) ... 00:38 Thoughtful, limited use of pharmaceuticals for health ... 00:44 Peptides: Orals, protocols, favorites (BPC-157, TA1, etc.) ... 00:47 GLP-1 agonists: Powerful but require careful dosing ... 00:51 Biohacks gone wrong: Dosing mishaps and psychedelic stories ... 00:55 Ben's three core tips: Family time, naps, and prayer ... 00:58   Our Amazing Sponsors: Wizard Sciences - Mitoblue Everything in the formula is there to help you think clearer, move better, and stay resilient mentally and physically - Methylene Blue, NMN, PQQ, Apigenin and Ginseng. Go to wizardsciences.com and look for MitoBlue. Use code NAT15 at checkout to get 15% off your purchase.   Mitolux NEW Second Generation - This second-generation red and near-infrared light therapy panel hits all the marks. Two new wavelengths—810nm and 940nm—target brain performance, deep muscle recovery, and circulation. I use GAMA mode when I want to lock in focus, and Fireplace 2 when I want to wind down. Get a Mitolux BTS2 Sunlamp for 10% off at https://mitolux.com/NAT10, NAT10 will be automatically applied at checkout.   LVLUP - Neuro Re-Generate the world's first liposomal triple peptide formula, designed to support mental clarity, focus, and overall brain health. Visit www.lvluphealth.com and use code NAT for 10% off your order.   Nat's Links: YouTube Channel Join My Membership Community Sign up for My Newsletter  Instagram  Facebook Group

Send us a textDr. Michael Koren shares insights from his presentation at the American College of Cardiology meeting in Chicago about a groundbreaking oral PCSK9 inhibitor that could lower cholesterol by 80% when combined with a statin. The development represents a significant advancement in treatment options for the 20% of patients who don't respond adequately to statins alone or experience statin intolerance. They also chat about Chicago and the importance of things in moderation.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Audio roundup of selected biopharma industry content from Scrip over the business week ended 4 April 2025. In this episode: pharma dodges tariffs for now; Marks's departure from FDA rattles industry; Phase 2b win for AstraZeneca's oral PCSK9; Hengrui renews global Phase 3 push; and Novo's new cardio results for semaglutide. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-MPJF4YP4NFAQ5JEDFBEIW62LBE/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

JACC Associate Editor Khurram Nasir, MBBS, FACC, speaks with author Michael J. Koren, MD, FACC, on his Featured Clinical Research study published in JACC and presented at ACC.25. This randomized, multicenter, double-blind, placebo-controlled, dose-ranging phase 2 study assessed efficacy, safety, and tolerability of AZD0780, a small molecule PCSK9 inhibitor. The study randomized 428 patients (426 started treatment) with hypercholesterolemia on standard-of-care statin therapy to daily oral administrations of AZD0780 1, 3, 10 or 30 mg, or matching placebo for 12 weeks. AZD0780 significantly reduced LDL-C levels versus placebo at all doses (from 35.3% to 50.7%) and demonstrated a safety and tolerability profile similar to placebo. These findings support further development of AZD0780 as part of a simple, oral regimen for lowering LDL-C beyond that achieved with statin therapy.

Μαζί με τον κ. Κοσκινά εστιάζουμε στις σύγχρονες θεραπευτικές στρατηγικές για τη δυσλιπιδαιμία, ξεκινώντας με τη συζήτηση γύρω από τις στατίνες και την εζετιμίμπη: ποια είναι η προτιμότερη προσέγγιση — συνδυασμός μέτριας έντασης στατίνης με εζετιμίμπη ή υψηλής έντασης στατίνη;Αναλύεται επίσης η θέση του μπεμπεδοϊκού οξέος, καθώς και η ραγδαία εξέλιξη των PCSK9 αναστολέων, από τα μονοκλωνικά αντισώματα στους RNA-based παράγοντες όπως το Inclisiran, έως τις νέες θεραπείες τρίτης γενιάς (π.χ. Lerodalcibep) και τις πρώτες προσπάθειες γονιδιακής θεραπείας με CRISPR.Η συζήτηση επεκτείνεται σε νεότερες κατηγορίες, όπως οι αναστολείς ANGPTL3 (π.χ. Evinacumab) και αναστολείς CETP (Obicetrapib), εξετάζοντας τη μελλοντική τους θέση στην καρδιαγγειακή πρόληψη.Τέλος, εξετάζονται οι εξελίξεις στην αντιμετώπιση της λιποπρωτεΐνης (a), με ελπιδοφόρα φάρμακα όπως τα Pelacarsen, Olpasiran, Lepodisiran, και το ανερχόμενο Muvalaplin, και γίνεται αναφορά στις αναμενόμενες νέες κατευθυντήριες οδηγίες και τις πιθανές αλλαγές που αυτές θα φέρουν.

A discussion on statins vs. PCSK9 inhibitors; My doctor said I should take a multivitamin instead of the long list of supplements I currently take. What do you think?

This is a replay of one of the most-downloaded episodes of AGE BETTER in 2024.     Take a deep dive into the heart of midlife cardiovascular wellness with this important episode of "Age Better," where host Barbara Hannah Grufferman talks with Dr. Melissa Tracy, a top-tier cardiologist from the RUSH University Medical Center. Dr. Tracy is also the Medical Director of the Cardiac Rehabilitation Program at RUSH.     Dr. Tracy gives a masterclass on statins - those powerhouse medications at the forefront of cholesterol management and heart disease prevention. But the question that lies at the core of this discussion is one that resonates with millions: Who really needs to be on statins? By tuning in, you'll get the knowledge and tools you need to make the decision that is right for you.     KEY TAKEAWAYS:  Understanding Statins: Learn how these powerful medications aid in reducing cholesterol and preventing cardiovascular disease.    Postmenopause and Heart Health: Discover the unique impact of statins for women in midlife.    Shared Decision-Making: The importance of patient-doctor collaboration in deciding if statins are right for you.    Coronary Calcium Score: Uncover how this test is crucial in assessing cardiovascular risks.    Side Effects & Alternatives: Insights into common side effects of statins and who should avoid them, plus a look at natural supplements and other cholesterol management strategies.    Personalized Healthcare: Dr. Tracy emphasizes individualized treatment plans and the role of lifestyle changes alongside statins.    Future-Focused Discussion: A sneak peek into ongoing assessments and evolving conversations in heart health management.    KEY LINKS:  Learn More About Dr. Melissa Tracy: https://doctors.rush.edu/details/1183  What is Cardiac Rehabilitation? https://www.kevinmd.com/2024/02/a-people-first-approach-to-cardiac-rehabilitation.html  USNews+WorldReport Article: https://www.usnews.com/news/health-news/articles/2024-03-05/statin-meds-cholesterol-what-you-need-to-know  Alternatives to Statins Referenced During the Episode:   Ezetimibe: https://www.mayoclinic.org/drugs-supplements/ezetimibe-oral-route/description/drg-20067172  Bempedoic Acid: https://www.mayoclinic.org/drugs-supplements/bempedoic-acid-oral-route/side-effects/drg-20484223?p=1  PCSK9 inhibitors: https://www.medicalnewstoday.com/articles/pcsk9-inhibitor#definition    Whether you're on a statin already, or giving it serious consideration … this episode will help you make the decision that is right for you.    Listen and Subscribe   Remember to subscribe or follow the "Age Better with Barbara Hannah Grufferman" podcast on platforms like Apple Podcasts, Spotify, and YouTube. Yep, you can watch it or just listen!     Share Your Ideas and Questions   Your questions have spurred many episodes, so please keep them coming! Share your ideas for topics and guest suggestions at agebetterpodcast@gmail.com  Learn more about your ad choices. Visit megaphone.fm/adchoices

“It's about symptoms and how you're doing and how you're feeling. It's not necessarily the number on the lab tests,” says Amy Killen, M.D. Amy Killen, M.D., a leading anti-aging and regenerative physician, joins us today to discuss science-backed methods to improve longevity, including stem cell therapies, hormone replacement, and more:  - Women's longevity stack (~2:00) - Hormone health (~4:40) - Hormone replacement therapy (HRT) (~6:05) - Different types of HRT (~7:37) - Killen's story (~9:07) - Stem cell therapy (~11:01) - Sexual health and stem cells (~17:00) - Nitric oxide (~18:10) - How to measure nitric oxide levels (~20:25) - Collagen and hyaluronic acid (~22:30) - Red light and PEMF (~23:36) - Killen's daily routine (~25:15) - Overrated practices in wellness culture (~26:29) - Modern medicine for longevity benefits (~29:45) - Testosterone replacement therapy (TRT) for men (~33:20) - Popular therapies and treatments (~36:40) - The future of longevity and women's health (~42:32) Referenced in the episode:  - Keep up with her @Dr.AmyBKillen (IG, FB, TikTok) - Follow her online (www.dramykillen.com)  - Check out her company (https://hopbox.life/)  - Learn more about her clinic (www.humanauthealth.com)   - Listen to Stacy Sims, Ph.D. on the mbg podcast episode #514  - Research on SGLT2 inhibitors (https://doi.org/10.1016/j.pcad.2023.10.003)  - Research on PCSK9 inhibitors (https://doi.org/10.1016/j.ajpc.2024.100701)  immy is a natural, effective solution to retune your immune system, while addressing inflammatory status and improving mental health and overall resilience.* Learn more about immy today at immy.co. *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. ​We hope you enjoy this episode, and feel free to watch the full video on YouTube! Whether it's an article or podcast, we want to know what we can do to help here at mindbodygreen. Let us know at: podcast@mindbodygreen.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

0:00- Intro               0:30- PhD process               8:00- Repetitiveness in expertise               14:40- Saturated fat, LDL, and ApoB               41:00- Statins, PCSK9 inhibitors               47:00- Human equivalent doses 

CardioNerds Dan Ambinder and Dr. Devesh Rai join cardiology fellows and National Lipid Association lipid scholars Dr. Jelani Grant from Johns Hopkins University and Dr. Alexander Razavi from Emory University. They discuss a case involving a patient with familial hypercholesterolemia. Dr. Archna Bajaj from University of Pennsylvania provides expert commentary. Drs. Jelani Grant and Alexander Razavi drafted notes. CardioNerds Intern Pacey Wetstein engineered episode audio. This episode is part of a case reports series developed in collaboration with the National Lipid Association and their Lipid Scholarship Program, with mentorship from Dr. Daniel Soffer and Dr. Eugenia Gianos. A classic finding in patients with familial hypercholesterolemia is the presence of markedly elevated levels of total and low-density lipoprotein cholesterol (LDL-C) with an LDL-C concentration of 190 mg/dL or greater. However, severe hypercholesterolemia is not inevitably present, and many patients who carry this diagnosis may have lower LDL-C levels. This case history describes a young woman whose mother and brother met clinical and genetic criteria for heterozygous familial hypercholesterolemia but who had only a mild elevation in LDL-C, falling to 130 mg/dL after dietary intervention. Despite this finding, genetic testing revealed the presence of the same genetic variants as were noted in her mother and brother. In addition, a second genetic variant predisposing them to cholesterol gallstone formation was identified in all three family members. If genetic testing had not been performed, the diagnosis may have been missed or delayed, resulting in an increased risk for vascular complications associated with familial hypercholesterolemia. This case supports the value of genetic testing of family members of those with familial hypercholesterolemia, even when LDL-C levels are not severely elevated. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls - Exposing an Unusual Presentation of Familial Hypercholesterolemia – National Lipid Association Familial hypercholesterolemia (FH) is among the most common autosomal co-dominant genetic conditions (approximately 1:200 to 1:300 for HeFH, 1:160,000 to 1:300,000 for HoFH). Genetic testing has a role for all first-degree relatives when a family history of FH is strongly suggestive, regardless of LDL-C level. Heterogeneity in ASCVD risk among individuals with FH is derived from background polygenic risk, clinical risk factors (e.g., timing of lipid-lowering initiation and adjacent risk factors), as well as subclinical atherosclerosis burden. In clinical or genetically confirmed FH, an LDL-C goal of 55 mg/dL is recommended. Beyond statins, FDA-approved non-statin therapies for FH include ezetimibe, PCSK9 mAb, bempedoic acid, inclisiran, evolocumab (only HoFH), lomitapide (only HoFH), and LDL apheresis. Notes - Exposing an Unusual Presentation of Familial Hypercholesterolemia – National Lipid Association What are the diagnostic criteria for FH? Dutch Lipid Clinic Network1 Variables: family history, clinical history, physical exam, LDL-C level, DNA (LDLR, APOB, PCSK9) Simon-Broome1 Variables: total or LDL-C, physical exam, DNA (LDLR, APOB, PCSK9), family history Emphasis on clinical history and physical exam reduces sensitivity U.S. Make Early Diagnosis Prevent Early Death (MEDPED) 1 Only one of the three where no genetic testing is required, may work well in cascade screening Variables: age, total cholesterol, family relative (and degree) with FH Definite, probable, possible, unlikely Emphasis on clinical history and physical exam reduces sensitivity

Please Subscribe and Review: Apple Podcasts | RSS Submit your questions for the podcast here News Topic: "History Comes In Patterns" Neil Howe: Civil War, Market Crashes, and The Fourth Turning | PBD #441 Show Notes: The Fourth Turning Is Here: What the Seasons of History Tell Us about How and When This Crisis Will End Elevated levels of serum per- and poly-fluoroalkyl substances (PFAS) in contact lens users of U.S. young adults Questions:    PFOAS in Contacts Chrissy writes: Good day, I know pfoas are everywhere but contacts too! I hate wearing glasses. Additionally most are UV blocking, which is something I want in my eyes. Should contacts be ditched! What do you or your family do?   Choosing a Functional Doc Chris writes:  Hello, Long time fan boy... Any advice on picking a good functional medicine doctor in my local area? Google search? Anything to look for, or look out for? I found a local MD with a long time in family medicine, who transitioned to integrative holistic medicine about 10 years ago, and then got an ABoIM about 5 years ago. I can only assume that ABoIM is a board certificate of some kind? Sounds like integrative medicine is similar to functional medicine? I ask because I have become a moody AF little bitch after a year on a statin. My original family doc and my precision health report says the cholesterol is on the risky to highly risky side of things. I have always wanted to get off of the statin, and try the PCSK9 inhibitor you discussed some months back. Finally aiming to start that transition. Any help or advice on doc selection is appreciated! Cheers, Chris R   Sponsor: The Healthy Rebellion Radio is sponsored by our electrolyte company, LMNT. Proper hydration is more than just drinking water. You need electrolytes too! Check out The Healthy Rebellion Radio sponsor LMNT for grab-and-go electrolyte drink mix packets and the new LMNT Sparkling electrolyte performance beverage! Click here to get your LMNT electrolytes Transcript: Coming soon!  

In episode 529 of Sigma Nutrition Radio, we discuss all things related to cholesterol, atherosclerosis, heart disease, and dietary fat. The discussion extensively covers the impact of LDL cholesterol and ApoB on atherosclerotic plaque progression, cardiovascular events, and the benefits of early LDL lowering interventions, particularly through the use of PCSK9 inhibitors alongside statins. We address misconceptions prevalent in the low-carb and carnivore communities, dissect claims regarding saturated fats, and elucidate why atherosclerosis predominantly affects arteries and not veins. The episode sheds light on the nuanced mechanisms of cholesterol metabolism, the significance of different lipid particles, and the limited dietary impact on LP(a) levels. Comprehensive evidence-based insights and practical recommendations for dietary patterns and cardiovascular health interventions are provided, offering clarity on these complex topics. Note: This discussion is hosted by Simon Hill, and originally appeared as an episode of The Proof podcast. Links: Subscribe to Sigma Nutrition Premium Receive our free weekly email: the Sigma Synopsis Episode with Professor Chris Packard Timestamps: 07:19 Understanding Cholesterol and Lipoproteins 14:35 The Role of ApoB in Cardiovascular Risk 25:10 Atherogenic Lipoproteins and Their Impact 37:42 Causal Pathways and Biomarkers in Heart Disease 47:02 Understanding Residual Risk and Triglycerides 49:46 Paul Saladino's Claims on LDL and Metabolic Health 01:03:01 Addressing Concerns About Lowering Cholesterol 01:16:16 The Importance of Early Intervention in Cholesterol Management 01:23:36 The Future of Cholesterol Management and Gene Editing 01:28:24 Atherosclerosis in Arteries vs. Veins 01:36:08 Dietary Interventions to Lower ApoB Levels 01:47:55 Modifying Keto Diet for Better Health Outcomes 01:56:33 Plant-Based Diets and Fat Consumption 02:05:10 Understanding Lp(a) and Its Impact on Health Subscribe to Sigma Nutrition Premium

This case report explores the intricacies of familial hypercholesterolemia (FH), delving into its genetic basis, atherosclerotic cascade, and early-onset cardiovascular complications. It examines established diagnostic criteria and emphasizes personalized management, including statins, novel therapies, and lifestyle modifications. CardioNerds cofounders (Drs. Amit Goyal and Danial Ambinder) join Dr. Irfan Shafi, Dr. Preeya Prakash, and Dr. Rebecca Theisen from the Wayne State University/DMC and Central Michigan University at Campus Martius in Downtown Detroit for some holiday ice-skating! They discuss an interesting pediatric case (see case synopsis below). Dr. Luis C Afonso provides the Expert CardioNerd Perspectives & Review segment for this episode. Audio editing by CardioNerds academy intern, Pace Wetstein. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Case Synopsis FH, a 9-year-old female with no previous medical history, recently moved back to the US from Iraq. She presented to establish care and discuss new-onset chest pain and dyspnea. A systolic ejection murmur was noted during her initial visit to the pediatrician, prompting cholesterol testing and a cardiology referral. Testing revealed, alarming cholesterol levels (Total Cholesterol: 802 mg/dL, LDL: 731 mg/dL, Triglycerides: 123 mg/dL) prompted concern for cardiac involvement. Due to persistent symptoms, FH was transferred to Children's Hospital of Michigan. Despite normal findings on EKG and chest x-ray, a 2/6 systolic murmur was noted. She was discharged with a cardiology clinic follow-up. However, two days later, FH experienced severe chest pain at rest, sweating, and difficulty breathing. She was transported to Children's Hospital again, and her troponin level measured 3000, and her total cholesterol was 695 mg/dL. An echocardiogram revealed valvar and supravalvar aortic stenosis, necessitating collaboration between Pediatric and Adult cardiology teams. CTA thorax revealed severe supravalvular stenosis, a hypoplastic right coronary artery, and significant coronary artery obstructions. Diagnostic cardiac catheterization confirmed severe aortic stenosis and coronary artery disease, leading to the decision for surgical intervention. FH underwent the Ross operation, left main coronary artery augmentation, and right coronary artery reimplantation. Intraoperatively, atherosclerotic plaques were observed in multiple cardiac structures. FH's recovery was uneventful, discharged on a regimen including Atorvastatin, Ezetimibe, evolocumab, and antiplatelet therapy. Persistent high LDL levels required regular plasmapheresis. Plans for evaluations in Genetics, Lipid Clinic, Endocrine, and Gastroenterology were made, potentially leading to a liver transplant assessment. Given the severity of her condition, a heart/liver transplant might be considered in the future. Conclusion: This case of FH highlights the complex presentation of severe aortic stenosis and coronary artery disease in a pediatric patient. Urgent diagnosis, interdisciplinary collaboration, and aggressive management were crucial. The case underscores the importance of comprehensive care for pediatric patients with rare cardiac conditions, emphasizing collaboration between specialties for optimal outcomes and long-term well-being. Case Media Pearls - Familial Hypercholesterolemia Mutations in LDLR, ApoB, or PCSK9 genes disrupt LDL-C clearance, leading to a cascade of events culminating in accelerated atherosclerosis and early-onset cardiovascular complications (e.g., CAD, aortic stenosis, PAD, stroke). Diagnosis of familial hypercholesterolemia relies on ...

“Menopause is inevitable, but suffering through it is not," says Mary Claire Haver, M.D. Mary Claire, a board-certified OBGYN and certified menopause practitioner, joins us to discuss everything a woman needs to know during this hormonal transition and beyond, including: - Old vs. new menopause (~00:07) - Signs of peri menopause in 30s, 40s & 50s (~02:04) - Sleep deprivation during menopause (~05:09) - Menopause weight gain (~06:36) - How to enhance body composition as you age (~09:25) - Protein needs for women (~14:20) - The link between food & hot flashes (~16:09) - Pros & cons of hormone replacement therapy (~18:43) - How to know if you're a good candidate for HRT (~25:02) - Best questions to ask your doctor (~27:23) - Why we should have annual midlife wellness visits (~28:28) - The future of menopause care (~31:23) - A drug that can prolong estrogen production (~33:02) - How to measure estrogen swings (~35:10) - How to be your own menopause advocate (~39:35) Visit shop.mindbodygreen.com/whey20 to get 20% off whey protein isolate+. Cannot combine with gift cards or other discount codes. Referenced in the episode: - Mary Claire's book, The New Menopause - The Galveston Diet - Follow Mary Claire on Instagram - mbg Podcast episode #529, with Lisa Mosconi, Ph.D. - mbg Podcast episode #480, with Peter Attia, M.D. - Statins Peter mentions: PCSK9 inhibitors, Ezetimibe, and Bempedoic Acid - WHI study on frailty - A study on estrogen therapy & dementia - menopause.org - Mary Claire's Menopause Empowerment Guide - Tests to ask for at the doctor - Oviva Therapeutics We hope you enjoy this episode, and feel free to watch the full video on YouTube! Whether it's an article or podcast, we want to know what we can do to help here at mindbodygreen. Let us know at: podcast@mindbodygreen.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

As I've been researching and writing Boundless 2.0, I've found myself reevaluating many of the health and fitness strategies that I previously endorsed.In this episode, prepare to have your perspective challenged as I discuss some of the significant shifts in thinking I've undergone while exploring the latest science and experimenting with biohacking. To kick off the show, I discuss one of the biggest areas where I've updated my thinking — the ketogenic diet. While I was previously gung-ho about strict therapeutic ketosis for all sorts of applications, I now have a more nuanced view that involves limiting carbohydrates during the day for enhanced focus and consuming 200 to 300g in the evening to support better sleep and hormonal balance. Additionally, I've moved away from a saturated fat-heavy keto diet to a Mediterranean-style approach with foods like avocados, olives, oily fish, and olive oil. When it comes to exercise, I used to be that guy who obsessively crushed two-a-day workout sessions. But the more I dig into the research, the more I've come to understand the importance of staying within the "Goldilocks Zone" — enough training to accrue benefits, but not so much that you risk overtraining. Another controversial mind shift I've experienced is around statins, which was prompted by my advanced cardiac screening. My Cleerly test revealed plaque buildup, leading me to start a PCSK9 inhibitor and a daily dose of rosuvastatin and acetamide. While I still don't think these drugs should be blindly taken, in some cases the benefits can outweigh the risks if properly monitored. My view on cold exposure has also slightly changed after digging into research. I used to be all about long ice baths and open-water cold swims, but now I've shifted to shorter, more frequent cold exposures. (You'll hear multiple times throughout this show that optimizing your body is all about finding the right balance and avoiding excessive stress.) This show also covers topics like the hidden benefits of aspirin, ginger, and yes... even "dick pills." Plus, you'll gain insights into sleep hacking, why I'm taking a more discerning stance on cannabis, and the dangers of extreme biohacking. For the full show notes, visit: https://bengreenfieldlife.com/470 Episode Sponsors: Paleovalley: Go to paleovalley.com/ben to get 15% off your first order. C60: Visit shopc60.com/ben-greenfield and use code GREENFIELD15 for 15% OFF your first order. Mito Red Light: Go to mitoredlight.com and use code BGLIFE to save 5%. Ion Layer: Use code GREENFIELD at ionlayer.com/ben for $150 off your kit and start reaping the benefits of NAD+. Jigsaw Health: Visit JigsawAC.com and use "GREENFIELD10" to get 10% off.See omnystudio.com/listener for privacy information.